Tenaya Therapeutics gets FDA RMAT designation for TN-401
FDA granted Tenaya Therapeutics a Regenerative Medicine Advanced Therapy (RMAT) designation for TN-401 to treat PKP2-associated arrhythmogenic right ventricular cardiomyopathy.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.